This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
“Execution of this license agreement with Bio-Rad, a global leader in the life science research community, continues to underscore the value of the Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi,” said Roland Kreutzer, Ph.D., Managing Director of Alnylam Europe AG.
“This agreement brings the number of licenses that Alnylam has granted to more than 20, including 13 with research product suppliers. In fact, we believe that over 75 percent of industrial sales of siRNAs for research purposes are currently being made under access to Alnylam’s intellectual property.”
Alnylam’s intellectual property estate includes certain fundamental patents and patent applications that claim the broad structural and functional properties of synthetic RNAi products. These include the Kreutzer-Limmer I and II patents, acquired through the 2003 merger of Alnylam with Ribopharma.